Rocket PHARMACEUTICALS, Inc. (RCKT) intrinsic value & 10-year financials
Rocket PHARMACEUTICALS, Inc. (RCKT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $0, with an average return on invested capital of -76.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.18
- Market cap
- $242.2M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -76.0%
- Free cash flow (FY2025)
- -$190.5M
RCKT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$223.1M | -$2.01 | -$190.5M | — | -85.2% |
| FY2024 | $0 | -$258.7M | -$2.73 | -$215.6M | — | -69.9% |
| FY2023 | $0 | -$245.6M | -$2.92 | -$211.4M | — | -62.7% |
| FY2022 | $0 | -$221.9M | -$3.26 | -$186.5M | — | -72.6% |
| FY2021 | $0 | -$169.1M | -$2.67 | -$128.8M | — | -72.3% |
| FY2020 | $0 | -$139.7M | -$2.52 | -$95.2M | — | -80.0% |
| FY2019 | $0 | -$77.3M | -$1.58 | -$87.9M | — | -75.0% |
| FY2018 | $0 | -$74.5M | — | -$55.2M | — | -90.1% |
| FY2017 | $0 | -$29.5M | — | -$16.7M | — | — |
| FY2016 | $0 | -$42.9M | — | -$5.8M | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ROCKET PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ROCKET PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just -76.0% ROIC.
ROCKET PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ROCKET PHARMACEUTICALS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.